Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

Original reporting
Published Nov 16, 2026, 10:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$OMER
Bearish
high confidence
Mentioned
$OMER
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OMERBearishMed
01

Why it matters

The combination of GAAP loss optics and a continued European regulatory setback is presented as the primary driver of the after-hours selloff.

02

Market read

Company-specific earnings optics plus an EMA negative opinion are likely to dominate near-term positioning for Omeros.

03

What to watch

Investors may be underweighting the adjusted EPS and gross revenue beat, and overemphasizing the non-cash derivative impact relative to the underlying operating trend.

Relevance 7/10Novelty 6/10Timing: after-hours reaction to Q3 2026 results and EMA negative opinion

Background

Omeros reported Q3 2026 results with adjusted EPS and revenue beats, but a large GAAP net loss and a negative EMA CHMP opinion on narsoplimab for TA-TMA.

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

Omeros shares fell 10.4% after hours after Q3 results showed a GAAP net loss of $57.4M despite adjusted EPS and revenue beats.

Expected impact

Likely further downside or elevated volatility as investors reprice regulatory and GAAP-loss risk versus the adjusted earnings beat.

Evidence & confidence

The article ties the selloff directly to the GAAP net loss driven by non-cash derivative mark-to-market and a new European regulatory negative opinion, both immediate sentiment drivers.

Market effects

Highlights how biotech investors can punish GAAP optics and regulatory setbacks even when adjusted profitability and revenue improve.

European regulatory sentiment (EMA CHMP negative opinion) is a direct overhang for Omeros’ TA-TMA program.

Reinforces cross-market read-through that EMA decisions can quickly pressure US-listed biotech sentiment.

Counterpoint

The GAAP loss is largely non-cash from derivative mark-to-market, while operating income and adjusted EPS improved, suggesting the selloff may overreact to accounting optics.

Key entities

  • Omeros

    Seattle-based biopharmaceutical company whose Q3 results and EMA regulatory outcome drove the after-hours decline.

  • European Medicines Agency (EMA) CHMP

    Issued a negative opinion on narsoplimab for TA-TMA after re-examination in October.

  • narsoplimab (TA-TMA)

    Therapy program referenced as receiving a negative EMA opinion, weighing on sentiment.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q